Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Servier

Private
#Oncology#Cardiovascular & Metabolic#Neurology#Immunology & Inflammation

French independent pharmaceutical group owned by a non-profit foundation, focused on oncology, cardiometabolic disease and neurology, with a marketed portfolio including Tibsovo (ivosidenib) and Voranigo (vorasidenib) and a growing rare-neurology pipeline built through acquisitions.

Company Info

Sector:Pharmaceuticals
Headquarters:Suresnes, France
Founded:1954
Website:servier.com

Upcoming Milestones & Key Dates

2027-01
Clinical readout

Sevasemten Phase 2 LYNX study in Duchenne muscular dystrophy due to complete

2026-12
Data presentation

Full GRAND CANYON (Becker muscular dystrophy) dataset analysis and presentation

Clinical Development Pipeline

Sevasemten

Target: Fast skeletal myosin inhibitor
Becker muscular dystrophy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Voranigo (vorasidenib)

Target: IDH1/IDH2 inhibitor
IDH-mutant grade 2 glioma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Tibsovo (ivosidenib)

Target: IDH1 inhibitor
IDH1-mutant AML and cholangiocarcinoma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Olivier Laureau

President, Servier Group

David K. Lee

Chief Executive Officer, Servier Pharmaceuticals (US)

Careers & Job Openings

See all open roles

All
Global
Apply Now →